Gupta Harshit, Girma Brook, Jenkins Jack S, Kaufman Sarah E, Lee Christopher A, Kaye Alan D
University of California Los Angeles.
Louisiana State University Shreveport.
Health Psychol Res. 2021 Jul 10;9(1):25532. doi: 10.52965/001c.25532. eCollection 2021.
This is a comprehensive review of the literature regarding the use of milnacipran in treating fibromyalgia. A chronic pain disorder with other system disturbances, fibromyalgia is often resistant to many therapeutic approaches. This review presents the background, evidence, and indications for using milnacipran as a treatment option for this condition.
The definition of fibromyalgia has evolved over many years as it is a relatively tricky syndrome to measure objectively. Today, it is characterized by chronic, widespread pain accompanied by alterations in sleep, mood, and other behavioral aspects. A variety of therapeutic regimens currently used to treat the syndrome as a singular approach are rarely effective.Milnacipran is one of three drugs currently approved by the FDA for the treatment of fibromyalgia. It acts as a serotonin and norepinephrine reuptake inhibitor, which results in decreased pain transmission. Milnacipran remains an effective treatment option for fibromyalgia in adults and needs to be further evaluated with existing therapeutic approaches.
Fibromyalgia is a broad-spectrum disorder primarily characterized by chronic pain coupled with disturbances in cognitive functioning and sleep. The progression of this syndrome is often debilitating and significantly affects the quality of life. Milnacipran is one of three FDA-approved drugs used to alleviate the symptom burden and is comparatively more therapeutic in specific domains of fibromyalgia. A more holistic approach is needed to treat fibromyalgia effectively and further research, including direct comparison studies, should be conducted to fully evaluate the usefulness of this drug.
本文是关于米那普明治疗纤维肌痛的文献综述。纤维肌痛是一种伴有其他系统紊乱的慢性疼痛疾病，通常对多种治疗方法均有抵抗性。本综述介绍了将米那普明作为该疾病治疗选择的背景、证据及适应证。
由于纤维肌痛是一种相对难以客观测量的综合征，其定义在多年间不断演变。如今，它的特征是慢性广泛性疼痛，并伴有睡眠、情绪及其他行为方面的改变。目前用于单独治疗该综合征的各种治疗方案很少有效。米那普明是目前美国食品药品监督管理局（FDA）批准用于治疗纤维肌痛的三种药物之一。它作为一种5-羟色胺和去甲肾上腺素再摄取抑制剂，可减少疼痛传递。米那普明仍是治疗成人纤维肌痛的有效选择，需要与现有的治疗方法进行进一步评估。
纤维肌痛是一种主要以慢性疼痛以及认知功能和睡眠障碍为特征的广谱疾病。该综合征的进展通常使人衰弱，并显著影响生活质量。米那普明是FDA批准用于减轻症状负担的三种药物之一，在纤维肌痛的特定领域相对更具治疗作用。需要一种更全面的方法来有效治疗纤维肌痛，应开展进一步研究，包括直接比较研究，以充分评估该药物的效用。
